IL6 and cancer: The combined effects of Oligo-Fucoidan and olaparib suppressed glucose uptake and lactate production (Fig. 5E, F) and decreased Glut-1, PFKL, RPIA and p-PKM2 and the IL-6/p-EGFR/p-AMPK/PD-L1 network (Fig. 5D), which can reprogram cancer cell energy expenditure and the PD-L1/PD-1 interaction between TNBC cells and T effector cells, enhancing immune checkpoint control.